Bhanwar Lal Jat1* and Ranjeeta Kumari2
1Dayanand College, MDS University Ajmer, Rajasthan India
2Department of Biotechnology, Mewar University Chittorgarh, Rajasthan India
A B S T R A C T
Pneumonia is the second most common nosocomial infection in the United States and is a leading cause of death due to hospital-acquired infections. Ventilator-associated pneumonia (VAP) is a form of nosocomial pneumonia that occurs in patients receiving mechanical ventilation for longer than 48 hours. The incidence of VAP is 22.8% in patients receiving mechanical ventilation, and patients receiving ventilatory support account for 86% of the cases of nosocomial pneumonia. Furthermore, the risk for pneumonia increases 3- to 10-fold in patients receiving mechanical ventilation. Ventilator-associated pneumonia (VAP) is a major cause of hospital morbidity and mortality despite recent advances in diagnosis and accuracy of management. However, as taught in medical science, prevention is better than cure is probably more appropriate as concerned to VAP because of the fact that it is a well preventable disease and a proper approach decreases the hospital stay, cost, morbidity and mortality. The aim of the study is to critically review the incidence and outcome, identify various risk factors and conclude specific measures that should be undertaken to prevent VAP. We studied patients randomly, kept on ventilatory support for more than 48 h.
Keywords: Azithromycin, Oro-dispersible tablet, Optimization, Disintegration time, FT-IR; Simplex lattice, Wetting time.